Needham & Company LLC restated their buy rating on shares of CTI BioPharma (NASDAQ:CTIC) in a research note issued to investors on Tuesday, AnalystRatings.com reports. The firm currently has a $4.00 price target on the biopharmaceutical company’s stock.
Shares of CTIC stock opened at $0.98 on Tuesday. CTI BioPharma has a 52 week low of $0.60 and a 52 week high of $1.59. The firm has a 50 day moving average of $0.81 and a two-hundred day moving average of $0.80.
CTI BioPharma (NASDAQ:CTIC) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. CTI BioPharma had a negative net margin of 177.54% and a negative return on equity of 78.10%. The business had revenue of $2.29 million during the quarter.
CTI BioPharma Company Profile
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Featured Article: Buy Rating
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.